TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.240
+0.120 (10.71%)
Mar 9, 2026, 3:27 PM EDT - Market open
TScan Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 10.33 | 2.82 | 21.05 | 13.54 | 10.14 | |
| Revenue Growth (YoY) | 266.65% | -86.62% | 55.52% | 33.47% | 834.65% | |
| Cost of Revenue | 112.55 | 107.35 | 88.15 | 59.82 | 44.95 | |
| Gross Profit | -102.23 | -104.53 | -67.1 | -46.28 | -34.81 | |
| Selling, General & Admin | 31.59 | 30.29 | 26.35 | 20.35 | 13.83 | |
| Operating Expenses | 31.59 | 30.29 | 26.35 | 20.35 | 13.83 | |
| Operating Income | -133.81 | -134.82 | -93.46 | -66.64 | -48.64 | |
| Interest Expense | -2.77 | -3.65 | -3.76 | -1.18 | - | |
| Interest & Investment Income | 8.82 | 12.07 | 8 | 1.59 | 0.02 | |
| EBT Excluding Unusual Items | -127.77 | -126.41 | -89.22 | -66.22 | -48.63 | |
| Merger & Restructuring Charges | -2 | - | - | - | - | |
| Other Unusual Items | - | -1.09 | - | - | - | |
| Pretax Income | -129.77 | -127.5 | -89.22 | -66.22 | -48.63 | |
| Net Income | -129.77 | -127.5 | -89.22 | -66.22 | -48.63 | |
| Net Income to Common | -129.77 | -127.5 | -89.22 | -66.22 | -48.63 | |
| Shares Outstanding (Basic) | 130 | 112 | 48 | 24 | 12 | |
| Shares Outstanding (Diluted) | 130 | 112 | 48 | 24 | 12 | |
| Shares Change (YoY) | 15.88% | 134.15% | 98.89% | 106.20% | 1173.20% | |
| EPS (Basic) | -1.00 | -1.14 | -1.87 | -2.75 | -4.17 | |
| EPS (Diluted) | -1.00 | -1.14 | -1.87 | -2.75 | -4.17 | |
| Free Cash Flow | -139.73 | -114.65 | -64.5 | -70.73 | -58.62 | |
| Free Cash Flow Per Share | -1.08 | -1.02 | -1.35 | -2.94 | -5.03 | |
| Operating Margin | -1296.01% | -4787.68% | -444.00% | -492.32% | -479.65% | |
| Profit Margin | -1256.81% | -4527.66% | -423.86% | -489.26% | -479.49% | |
| Free Cash Flow Margin | -1353.28% | -4071.27% | -306.45% | -522.56% | -578.03% | |
| EBITDA | -130.95 | -130.71 | -88.1 | -61.5 | -45.31 | |
| D&A For EBITDA | 2.87 | 4.11 | 5.36 | 5.14 | 3.33 | |
| EBIT | -133.81 | -134.82 | -93.46 | -66.64 | -48.64 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.